

Day 3 May 25 (Fri.)

Scientific Program Educational Session Oral Session Social Event Plenary Session English Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
Sapporo Gebunkan	Room1	Nitori Culture Hall (1F)						SL-01 Special Lecture 01								
	Room2	Zuiseitsu (3F)	Symposium 18 inherited dystonia-update		O-26 Parkinsonism and Related disorders (Imaging 2)		LS-23 Takeda Pharmaceutical Company Limited.	AW-02 2016 Japanese Society of Neurology Award Winner Lecture	SL-02 Special Lecture 02	Special Program The future prospects of board-certified neurologists in Japan						
	Room3	Hourai (3F)	Hot Topics 05 Recent advances in noncoding RNA-involved neurodegeneration in ALS and SCA		O-27 Cerebrovascular disease (Clinical research 2)		LS-24 Pfizer Japan Inc./ Eisai Co., Ltd.			Overcome the Challenges of Neurological Disorders 04 Exploring genomic bases of neurological disease						
	Room4	Reimei (3F)	Symposium 19 Pre-and inhospital stroke management for hyper acute stroke		O-28 Cerebrovascular disease (Clinical research 3)		LS-25 Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd.			Symposium 25 Neuromodulation and motor training using novel devices						
	Room5	Seiryu (3F)	Symposium 20 Cutting-edge of genomic medicine essential for neurologist		O-29 Neuroinfection (Clinical research)		LS-26 AbbVie GK			Hot Topics 06 Cutting edge and perspective of investigator-led clinical trials for neurological disorders in Japan						
	Room6	Gyokuyou (3F)	Symposium 21 How do we prevent burnout in neurologists?		O-30 Neurophysiology (Clinical research)		LS-27 Stryker Japan K.K.			Symposium 26 The latest in Charcot-Marie-Tooth disease -diagnosis and care-						
Royton Sapporo	Room7	Castle (1F)	Symposium 22 Future perspective in Sports Neurology ~ from basics to clinical practice ~		O-31 Peripheral neuropathy/ Metabolic disorders (Clinical research)		LS-28 Nihon Medi-Physics Co.,Ltd.		Symposium 27 the "new wave" of CNS stimulation therapy							
	Room8	Empress Hall (2F)	Symposium 23 New frontier of epileptogenicity: translatability between basic and clinical fields		O-32 Epilepsy		LS-29 Otsuka Pharmaceutical Co. Ltd./ UCB Japan Co. Ltd.		Symposium 28 Cross-interaction of neuro-immune axis in autoimmune disorders of the CNS			ES-05 Novartis Pharma K.K.				
	Room9	Regent Hall (2F)	Symposium 24 Pathological basis and therapeutic strategy for neuropsychiatric symptoms		O-33 Parkinsonism and Related disorders (Biomarkers)		LS-30 Mitsubishi Tanabe Pharma Corporation		Symposium 29 Alzheimer's disease up to date			ES-06 Eli Lilly Japan K.K.				
	Room10	Highness Hall (2F)	LM-07 Lecture Marathon 07	LM-08 Lecture Marathon 08	O-34 Neurogenetics/ Gene therapy (Basic research)		LS-31 Bristol-Myers Squibb/ Pfizer Japan Inc.		LM-09 Lecture Marathon 09	LM-10 Lecture Marathon 10		ES-07 Biogen Japan Ltd. / Eisai Co., Ltd.				
	Room11	Crystal Room A (2F)			O-35 Dementia (Imaging)		LS-32 Nippon Zoki Pharmaceutical Co.,Ltd.		International Education Course 03 functional neurosurgery~update	International Education Course 04 Therapeutic approach of Multiple Sclerosis						
	Room12	Crystal Room B (2F)			O-36 Neuroscience 1		LS-33 Actelion Pharmaceuticals Japan Ltd.									
	Room13	Crystal Room C (2F)			O-37 Neuroimmunology (MS and NMO2)											
	Room14	Pearl Hall AB (20F)			O-38 Neurorehabilitation											
Sapporo Education and Culture Hall	Room15	Main Hall (1F)														
	Room16	Small Hall (1F)														
	Room17	301 (3F)					LS-34 Alexion Pharma GK									
Royton	Poster Session	Royton Hall (3F)	Poster Preparation				Poster Round				Poster Session		Poster Removal			

DAY 3